Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses frontal fibrosing alopecia and reports no new clinical results; the authors highlight the need for randomized controlled trials on 5AR inhibitors to assess their efficacy and safety.

This study found that the total testosterone/dihydrotestosterone ratio is significantly higher in women with polycystic ovary syndrome and is associated with a worse metabolic profile in both PCOS and healthy women.

This study found that in male rats, hesperidin co-administration ameliorated finasteride-induced testicular toxicity by reducing oxidative stress and improving antioxidant status, sperm parameters, and enzyme activity compared to finasteride treatment alone.

This study reviews the psychological side effects of finasteride, noting a potential association between 5-AR inhibitors and increased depressive symptoms, but emphasizes that the causal link to suicidal ideation remains unclear; the authors recommend mental health screenings and close monitoring for patients starting this medication.

In this study, researchers used computational methods to identify six phytochemicals from nettle, saw palmetto, and fenugreek as effective binders to 5-alpha reductase, with Jamogenin showing enhanced stability when encapsulated in lipid nanoparticles.

This study identified six molecules from herbal extracts that effectively bind to 5-alpha reductase (5-AR), with Jomogenin showing high binding stability when encapsulated in lipid nanoparticles, suggesting their potential for further experimental analysis to aid hair follicle growth.

In this computational study, researchers identified six phytochemicals, including Jamogenin, that effectively bind to the enzyme 5-AR, potentially promoting hair growth, and found that encapsulating Jamogenin in lipid nanoparticles enhances its stability.

This study suggests that 5AR inhibitors may reverse decreased expression of growth factor genes in human hair follicles under testosterone stimulation, indicating involvement of type I 5AR in hair growth.

This article reviews the role and controversies of 5α-reductase inhibitors like finasteride and dutasteride in managing prostate cancer, without presenting new research results.

This study explored the optimization of phytochemicals from Alstonia boonei to develop potential 5-alpha reductase inhibitors for Benign Prostatic Hyperplasia, finding promising analogs with enhanced binding affinity and stability compared to Finasteride, warranting further experimental validation.

In this laboratory study, finasteride administration in male rats lowered dihydrotestosterone levels and reduced c-Fos protein activation in brain tissue, indicating an impact on brain regions like the hippocampus, though these effects diminished after one month of withdrawing the drug.

This study found that the binding of finasteride to the enzyme 5a-reductase occurs at a slower rate than previously assumed, complicating the estimation of its real inhibitory constant.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

This study developed a validated HPLC method for accurately estimating dutasteride and its related compounds in capsules, suitable for routine and stability sample analysis.

This study identified potent dual inhibitors of 5α-reductases 1 and 2 that may aid in designing new drugs for related diseases.

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

This study found that SRD5a-3 is a highly efficient enzyme for converting hormones into androgens, with dutasteride being a much more potent inhibitor of SRD5a-3 than SRD5a-2.

Clinical studies reported that finasteride reduces scalp dihydrotestosterone levels and improves hair growth in men with androgenetic alopecia, supporting its role as a treatment option.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

Non-drug methods like diet, supplements, and aromatherapy can help manage hair loss and its emotional impact.

This review discusses plant extracts for dermatological use, highlighting evidence that some can reduce edema in chronic venous insufficiency or help treat actinic keratoses, but it reports no new clinical results.

In this study, low dose finasteride or dutasteride treatment was found to reduce prostate specific antigen levels in men with androgenetic alopecia, though levels sometimes remained stable or increased in those with low baseline PSA.

In this study, a nanoemulsion containing lavender, peppermint, and rosemary essential oils was developed and shown to promote hair growth in mice at a rate comparable to 2% topical minoxidil, suggesting a promising natural alternative due to its antioxidant and anti-inflammatory effects.

This review discusses the potential of herbal treatments like Saw palmetto, Green tea, and Rosemary as alternatives to conventional drugs for androgenetic alopecia, noting that these herbs may inhibit the 5-alpha-reductase enzyme and reduce hair loss with fewer side effects.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

This study found that silencing SRD5A2 and applying melatonin significantly boosted proliferation and migration of human hair follicle stem cells without causing differentiation, while increasing MT1 expression and reducing 5-alpha-reductase levels.

This study reported that newly synthesized phenanthridin-3-one derivatives effectively inhibit human steroid 5-α-reductase.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.